Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.27 +3.05%

+$0.36 today

Market cap
$288.53M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.13M

Average 0.11M

BNTC Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Benitec Biopharma Inc.NASDAQ: BNTC

Financing Cash Flow · Q3 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q3 FY2026 financing cash flow of $4.36M fell 84.7% year over year, behind the -1.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 95.6% from the prior quarter.

Context

  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -84.7% toward the trailing-twelve-month pace of -1.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.36M-95.6% QoQ
Last fiscal yearJun 2025
$70.49M+3.6% YoY
LTMMar 2026
$106.87M-1.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.7%——
1 year+3.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
70.49M USD
Year-over-year change
+3.6%
4-year CAGR
+33.0%

Financing Cash Flow vs competitors

How BNTC compares with its peers on the latest reported figures

  • BNTC's LTM Mar 2026 financing cash flow of $106.87M is the 2nd largest of the 10 companies compared; the peer median is $27.47M.
  • Its year-over-year change of -1.1% is the 5th highest of 10, against a peer median of -16.0%.
BNTC Competitors Peer median
Financing Cash Flow for BNTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SLDBSolid Biosciences Inc.LTM Mar 2026$243.75M +18.9%+37.5%—
BNTCBenitec Biopharma Inc.LTM Mar 2026$106.87M -1.1%——
OCGNOcugen, Inc.LTM Mar 2026$53.56M -16.0%-33.7%1199.5%
QSIQuantum-Si incorporatedLTM Mar 2026$47.05M -44.2%+268.4%2540.4%
NGNENeurogene Inc.LTM Mar 2026$30.68M -83.9%-23.0%—
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$27.47M +2.2%+154.7%185.9%
XOMAXOMA Royalty Corp.LTM Mar 2026$27.05M +108.3%+81.2%74.7%
GALTGalectin Therapeutics Inc.LTM Mar 2026$26.73M +25.9%+38.3%—
AUTLAutolus Therapeutics plcLTM Mar 2026$6.4M -122.8%—6.9%
PRTCPureTech Health plcFY2025$6.34M -62.6%-40.3%136.1%
Peer median (excluding BNTC) $27.47M-16.0%+37.9%161.0%

Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Net Income(13.88M)(18.21M)(19.56M)(21.75M)(37.92M)
Depreciation & Amortization424K392K381K343K396K
Deferred Income Tax00(714K)00
Stock-Based Compensation634K870K452K830K17.43M
Change in Working Capital8K1.04M714K1.17M(2.73M)
Accounts Receivables28K1K(50K)(176K)197K
Inventory(83K)(1.09M)(1.31M)00
Accounts Payables55K1.09M1.36M0(2.38M)
Other Working Capital8K1.04M714K1.35M(548K)
Other Non-Cash Items(16K)10K717K1K(764K)
Operating Cash Flow(12.83M)(15.9M)(18.01M)(19.4M)(23.59M)
Capital Expenditures(221K)(13K)(1K)(179K)(18K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(221K)(13K)(1K)(179K)(18K)
Debt Repayment00000
Common Stock Issued25.75M017.88M70.88M70.49M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.23M)0(1.87M)(2.85M)0
Financing Cash Flow22.52M016.02M68.03M70.49M
Effect of Forex Changes499K204K412K(8K)49K
Net Change in Cash9.97M(15.71M)(1.59M)48.44M46.93M
Free Cash Flow(13.05M)(15.91M)(18.01M)(19.58M)(23.61M)

Benitec Biopharma Inc.

NASDAQ:BNTC

Intrinsic Alpha fair value

Locked

Current Price

$8.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.